LeanLife Health Inc. Manufacturing Update LeanLife Health Inc. Manufacturing Update
VANCOUVER, British Columbia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- LeanLife Health Inc. (the “Company”, or “LeanLife”) (CSE: LLP) is pleased to provide an update of its processing and manufacturing.
Manufacturing equipment and processing:
The main equipment has been purchased and delivered to the new facility building in Canada comprised of some 4,000 square feet. The Company is awaiting the approval of permits to operate. Total expenditures for manufacturing and lab equipment including associated costs is some $700,000. Permitting for the manufacturing facility has conditions and requirements from municipal and provincial levels. The Company has engaged consultants to assist in this process.
Under previous arrangements, product was available in Europe, that the Company mainly used for sample purposes. Manufacturing was by way of a batch system, considered to be expensive, problematic, and outdated. The Company has acquired a continuous process manufacturing system bringing efficiency, computer monitoring and control with remote consultancy quality readout. Moreover, the main manufacturing unit is scalable, with features of additional units added vertically and/or adjacently. In this way additional production can be added in the same location or new locations in Canada or other countries in a very efficient manner. It is also possible to have a dedicated line for a single customer enabling customer features or monitoring.
Licensing and permitting:
The Company has begun the process of obtaining federal government certifications in Canada and the United States. The Company has engaged a consulting firm that specializes in this area, having offices in the US and Canada. Announcements will be made at an appropriate time. This will be an ongoing process. There are many endorsements and approvals that the Company desires to obtain. The Company has various approvals at present, but it is not prudent to reveal all at this point.
Planning:
As soon as permitting is complete the Company will begin process production. The Company has initial orders to fill, and inventory levels must be maintained to ensure that future order levels can also be filled.
Once production starts, the Company’s plan is to develop other location sites.
About LeanLife Health and the Omega 3 Market
LeanLife Health’s products are extracted from flax seeds, a plentiful and non-animal source of Omega 3. The products can be used as a food additive or as a nutraceutical and can be incorporated in foods such as bread, noodles, cheese, yogurt, juice and milk products. LeanLife Health’s industry leading Omega 3 product formulations are of the highest quality and contain no cholesterol. Products will be available in oil, emulsion and powder forms.
The global omega 3 market is expected to reach USD 7.32 billion by 2020, according to a report by Grand View Research, Inc.
For more information, please contact:
Stan Lis, CEO
Tel: 604 764-0518
E-mail: slis@leanlifehealth.com
Forward Looking Information
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control including, the Company's ability to compete with large food companies; sales of any potential products developed will be profitable; the ability to complete sales under the sales agreement. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
THE CSE HAS NEITHER APPROVED NOR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
